ES2219326T3 - 2-amino-6-anilino-purinas y su uso como medicamentos. - Google Patents

2-amino-6-anilino-purinas y su uso como medicamentos.

Info

Publication number
ES2219326T3
ES2219326T3 ES00916840T ES00916840T ES2219326T3 ES 2219326 T3 ES2219326 T3 ES 2219326T3 ES 00916840 T ES00916840 T ES 00916840T ES 00916840 T ES00916840 T ES 00916840T ES 2219326 T3 ES2219326 T3 ES 2219326T3
Authority
ES
Spain
Prior art keywords
amino
phenyl
hydroxy
ethyl
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00916840T
Other languages
English (en)
Spanish (es)
Inventor
Patricia Imbach
Hans-Georg Capraro
Jurg Zimmermann
Giorgio Caravatti
Pascal Furet
Wolfgang Karl-Diether Brill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2219326T3 publication Critical patent/ES2219326T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES00916840T 1999-02-18 2000-02-16 2-amino-6-anilino-purinas y su uso como medicamentos. Expired - Lifetime ES2219326T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9903762 1999-02-18
GBGB9903762.4A GB9903762D0 (en) 1999-02-18 1999-02-18 Organic compounds

Publications (1)

Publication Number Publication Date
ES2219326T3 true ES2219326T3 (es) 2004-12-01

Family

ID=10848053

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00916840T Expired - Lifetime ES2219326T3 (es) 1999-02-18 2000-02-16 2-amino-6-anilino-purinas y su uso como medicamentos.

Country Status (13)

Country Link
US (1) US6767906B2 (https=)
EP (1) EP1153024B1 (https=)
JP (1) JP2002537300A (https=)
CN (1) CN1183133C (https=)
AT (1) ATE265456T1 (https=)
AU (1) AU3804500A (https=)
BR (1) BR0008365A (https=)
CA (1) CA2360353A1 (https=)
DE (1) DE60010234T2 (https=)
ES (1) ES2219326T3 (https=)
GB (1) GB9903762D0 (https=)
PT (1) PT1153024E (https=)
WO (1) WO2000049018A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7296896A (en) * 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
JP2003531111A (ja) * 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0127615D0 (en) 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
DE60206782T2 (de) * 2001-07-09 2006-07-13 Aventis Pharmaceuticals Inc. Substituierte amide, sulfonamide und harnstoffe mit kinasehemmender wirkung
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1556129A4 (en) * 2002-10-15 2011-02-09 Irm Llc COMPOSITIONS AND METHODS OF INDUCING OSTEOGENESIS
WO2004054581A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
US7160834B2 (en) * 2003-03-18 2007-01-09 Exxonmobil Chemical Patents Inc. Soluble group-10 α-diimine catalyst precursors, catalysts and methods for dimerizing and oligomerizing olefins
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
WO2005047524A2 (en) * 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
JP5321061B2 (ja) 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
AR056556A1 (es) 2005-09-30 2007-10-10 Astrazeneca Ab Imidazo(1,2-a)piridina con actividad antiproliferacion celular
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101148449B (zh) * 2006-09-20 2010-08-11 浙江医药股份有限公司新昌制药厂 2-(6-喹啉氨基)-6-环丙氨基-9h-嘌呤成盐的方法
EP2330908A4 (en) * 2008-08-15 2011-11-23 Univ Georgetown FLUORESCENT CDK INHIBITORS FOR CANCER TREATMENT
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2012115575A1 (en) * 2011-02-21 2012-08-30 Biomatcell Ab Derivatives for inducing osteogenic differentiation
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP2953470B1 (en) 2013-02-07 2020-01-22 Merck Sharp & Dohme Corp. 2,6,7 substituted purines as hdm2 inhibitors
CN104447746A (zh) * 2013-09-18 2015-03-25 华安医学股份有限公司 一种活化ampk的化合物及其用途
KR101879422B1 (ko) * 2013-09-18 2018-07-17 베이징 한미 파마슈티컬 컴퍼니 리미티드 Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10722515B2 (en) * 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
CN110691782A (zh) * 2016-12-01 2020-01-14 艾普托斯生物科学公司 作为brd4和jak2双重抑制剂的稠合的嘧啶化合物及其使用方法
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
EP3947382B1 (en) 2019-03-26 2025-09-24 Academia Sinica Compounds for uses in pharmacological induction of hbf for treatment of sickle cell disease and beta-thalassemia
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE212535C (https=)
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5066655A (en) 1987-04-24 1991-11-19 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
CA1340361C (en) 1987-04-24 1999-02-02 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
KR910700253A (ko) 1989-01-31 1991-03-14 로버트 제이, 바란 N_6-치환-9-메틸아데닌: 신규한 부류의 아데노신 수용체 길항질
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
AU7296896A (en) * 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6255485B1 (en) * 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines

Also Published As

Publication number Publication date
DE60010234T2 (de) 2005-04-14
DE60010234D1 (de) 2004-06-03
CA2360353A1 (en) 2000-08-24
JP2002537300A (ja) 2002-11-05
GB9903762D0 (en) 1999-04-14
ATE265456T1 (de) 2004-05-15
HK1042479A1 (en) 2002-08-16
AU3804500A (en) 2000-09-04
CN1183133C (zh) 2005-01-05
US6767906B2 (en) 2004-07-27
CN1340054A (zh) 2002-03-13
EP1153024A1 (en) 2001-11-14
BR0008365A (pt) 2001-11-13
PT1153024E (pt) 2004-08-31
EP1153024B1 (en) 2004-04-28
US20020016329A1 (en) 2002-02-07
WO2000049018A1 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
ES2219326T3 (es) 2-amino-6-anilino-purinas y su uso como medicamentos.
JP2002537300A5 (https=)
US7091346B1 (en) Purine derivatives and processes for their preparation
ES3049198T3 (en) Benzimidazole carboxylic acids as glp-1r agonists
ES2297864T3 (es) Pirrolopirimidinas sustituidas y procesos para su preparacion.
ES2870524T3 (es) Derivado de piridina como inhibidor de ASK1, y método de preparación y uso del mismo
ES2236360T3 (es) Nuevos derivados de pirazolopidina sustituidos con carbamato.
ES2663601T3 (es) Derivados de quinazolina para el tratamiento de infecciones víricas y otras enfermedades
ES2238720T3 (es) Derivados heterociclicos de azahexano antiviralmente activos.
ES2927352T3 (es) Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos
WO2007034882A1 (ja) 新規アデニン化合物
US20190292155A1 (en) Therapeutic inhibitory compounds
SK98598A3 (en) Acyclic nucleoside derivatives
US6613936B1 (en) Synthesis of acyclic nucleoside derivatives
ES2231311T3 (es) Triazolotriazinonas y su uso.
HUP0003978A2 (en) Guanidinylation reagents
ES2180923T5 (es) Proceso para la preparacion de derivados de purina.
HK1042479B (en) 2-amino-6-anilino-purines and their use as medicaments
US10851112B2 (en) Anti-HCMV virus compound
EP0971923A2 (en) Synthesis of acyclic nucleoside derivatives
HK1016580B (en) Purine derivatives and processes for their preparation
US20120041198A1 (en) Process for Preparing 5,7 Diaminopyrazolo [1,5-a] Pyrimidine Compounds
NZ616642B2 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MXPA99007340A (en) Synthesis of acyclic nucleoside derivatives